SLC5A2 and diabetes mellitus: Currently, cardiovascular and kidney protective effects have been demonstrated for SGLT2 inhibitors in patients with and without DM, and the pathological or pharmacological mechanisms underlying these effects of SGLT2 inhibitors are attracting interest.